神戸大学 · 医学研究科/医学部

研究キーワードgynecologic oncology・endometrial cancer・ovarian cancer・uterine cervix cancer・PI3K AKT pathway・HPV-negative cervical cancer・interval debulking surgery・endometrial stromal sarcoma

ここは公開データのプレビューです。個別の適合理由、連絡角度、保存機能はログイン後に利用できます。

• Transformed Follicular Lymphoma (TFL) Predicts Outcome in Advanced Endometrial Cancer.2018 · Background: Transformed follicular lymphoma (TFL, ZC3H12D) was identified as a candidate tumor suppressor gene that contributes to cell-cycle arrest through regulation of Rb phosphorylation, but the clinical impact of TFL is unknown. The goal of this study was to evaluate the prognostic significance of TFL expression in advanced endometrial cancer.Methods: Tissue samples were obtained from 103 patients with Federation Internationale des Gynaecologistes et Obstetristes stage III-IV endometrial cancer. Associations between TFL expression and outcomes were evaluated using the Kaplan-Meier method and multivariate Cox proportional hazards regression models.Results: There were 24 TFL-low cases (23.3%) and the 10-year progression-free survival (PFS) and overall survival (OS) in these cases were lower than those for patients with normal TFL expression in univariate analysis (PFS, P = 0.003; OS, P = 0.106). In multivariate analysis, TFL status was a significant predictor for PFS [HR = 2.76; 95% confidence interval (CI), 1.45-5.28; P = 0.002] and OS (HR = 1.94; 95% CI, 0.91-4.11; P = 0.085), adjusted for covariates. The TFL gene maps to human chromosome 6q25.1, where estrogen receptor alpha (ERα) gene ESR1 is also located. Lack of ERα expression is a poor prognostic factor in early endometrial cancer. Among 41 ERα-low patients, 10-year PFS was significantly lower in 15 TFL-low cases (univariate analysis, P = 0.055; multivariate analysis, HR = 4.70; 95% CI, 1.68-13.20; P = 0.003).Conclusions: We identified TFL as a strong independent prognostic factor, regardless of ERα status.Impact: An investigation of the mechanism underlying tumor suppression by TFL may lead to new therapies for patients with advanced endometrial cancer. Cancer Epidemiol Biomarkers Prev; 27(8); 963-9. ©2018 AACR.
• A preoperative low cancer antigen 125 level (≦25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer2016 · 2016年06月, Jpn J Clin Oncol, 46(6) (6), 517 - 521, 英語, 国際誌
• Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix A Single-Institution Retrospective Review2015 · 2015年09月, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25(7) (7), 1300 - 1305, 英語, 国際誌
• Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery2013 · 2013年12月, GYNECOLOGIC ONCOLOGY, 131(3) (3), 531 - 534, 英語, 国際誌

• BRCA2 Kako_variantの治療抵抗性メカニズム解明と新規治療戦略の開発 若橋 宣, 須藤 保, 植野 さやか, 寺井 義人 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2025年04月01日 - 2028年03月31日2025 · KUID parsed section
• 卵巣癌の腟分泌物抽出miRNAによる早期診断と人工エクソソームを用いた核酸治療開発 寺井 義人, 高橋 良輔, 笹川 勇樹, 出口 雅士, 長又 哲史, 犬伏 祥子, 竹内 俊文, 南 康博, 谷村 憲司, 若橋 宣, 遠藤 光晴 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2024年04月01日 - 2027年03月31日2024 · KUID parsed section
• リンパ腫から見つかった「がん抑制遺伝子」が子宮体癌の治療戦略を変える。 若橋 宣 学術研究助成基金助成金／基盤研究(C), 2015年04月 - 2018年03月, 研究代表者 競争的資金2015 · KUID parsed section
• 子宮体癌の予後規定因子の解明‒新規がん抑制遺伝子 TFL発現の検討と臨床応用‒ 兵庫県医師会勤務医事業医学研究助成, 兵庫県立がんセンター, 2015年 - 2016年, 研究代表者2015 · KUID parsed section

• 公式プロフィール